Copy
Containing exclusive contributions from clinicians and charities, reviews
of the latest research and innovations from Dr Falk Pharma UK.
Header Image

Welcome to the first issue of the Dr Falk Pharma UK E-newsletter. Containing exclusive contributions from clinicians and charities, reviews of the latest research and of course, news of the latest events and innovations from Dr Falk Pharma UK. We hope our monthly E-newletters will help to keep you up to date with all things relevant to gastroenterology and hepatology.

Twitter Square

Please follow us on Twitter @drfalkpharma

Twitter Circle Twitter Website Circle Website
Clinical View Point

Clinical View Point

Alastair Forbes, Professor of Medicine (Gastroenterology & Nutrition) University of East Anglia, Norwich, puts the case for wider use of Budesonide in mild to moderate Crohn's.

"If a new form of steroid were to come on the market today, that relieved symptoms in patients with mild to moderate Crohn’s in 80% of cases, yet had less than ten per cent of the toxicity of prednisolone, would not medical professionals be queuing up to prescribe it for their patients?

Yet such a drug exists and has, in fact, been available for many years in this country. Indeed European guidelines for the management of Crohn’s(1) and more recent advice from NICE(2) recommend it as a first-line option for the management of ileocaecal Crohn’s and especially in patients who are at particular risk of experiencing side effects. So, the question is, why are many GPs and some consultants still not using budesonide as a first-line treatment for mild to moderate ileocaecal Crohn’s and other forms of inflammatory bowel disease (IBD) such as collagenous colitis for which good data also exist(3)?"

Click Here
Falk News

Falk News...

NICE/QIPP recognition that 'Once a day dosing' with Salofalk granules can improve patient outcomes & provide significant savings in Ulcerative colitis.

An innovative pilot study supported by Dr Falk Pharma UK demonstrated significant patient benefits and cost effectiveness of taking ‘once a day’ Salofalk Granules versus multiple daily tablets in mild to moderate Ulcerative Colitis has been approved by NICE as a case study for their prestigious QIPP Programme. (Quality, Innovation, Productivity and Prevention).(1)

Click Here to Read More
Dr Falk Meeting Update

The Eighth Dr. Falk/Core awards for excellence in clinical research and specialist nursing to be presented at the DDF meeting on 23rd June 2016

The Dr Falk/CORE Awards, now in their eighth year, aim to provide both acknowledgement of and reward to the amazing young clinical and nursing talent we have in the fields of gastroenterology and liver disease.

Click Here to Read More
Clinical Paper Review

Research Paper Review

Dr Riadh Jazrawi, Medical Director of Dr Falk Pharma UK, reviews the latest clinical papers in Hepatology and Gastroenterology.

COULD 5-ASAs PROVIDE NEW INFORMATION ON ULCERATIVE COLITIS?

5-Aminosalicylic acid, a specific drug for ulcerative colitis

Scandinavian Journal of Gastroenterology. 2015; Early Online, 1–9 ØYVIND HAUSO1,2, TOM CHRISTIAN MARTINSEN1,2 & HELGE WALDUM1,2

Click Here to Read More

IS pH6 VALUE MORE EFFECTIVE THAN pH7 FOR MESALAZINE RELEASE FORMULATIONS?

Gastrointestinal release behaviour of modified-release drug products: Dynamic dissolution testing of mesalazine formulations

International Journal of Pharmaceutics 484 (2015) 103–108 Alvaro Goyanes a, Grace B. Hatton a, Hamid A. Merchant a,b, Abdul W. Basit a,c

Click Here to Read More

META-ANALYSIS HIGHLIGHTS NEED FOR LONG-TERM OUTCOME STUDIES OF PBC

Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study

Gastroenterology 2014;147:1338–1349 Willem J. Lammers et al.

Click Here to Read More

HEADLINE: FIRST EVIDENCE THAT FXR AGONISTS MAY IMPROVE CLINICAL SCORE IN PATIENTS WITH BILE ACID DIARRHOEA

The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid

Aliment Pharmacol Ther 2015; 41: 54–64 J. R. F. Walters*, I. M. Johnston*, J. D. Nolan*, C. Vassie*, M. E. Pruzanski† & D. A. Shapiro‡

Click Here to Read More
Meetings Update

Meetings Update

The international Falk Symposium 201 "Gut-Liver Interactions: from IBD to NASH" will take place in Innsbruck, Austria, on 11-12 March 2016, click here for more details. It will provide opportunities to hear some leading specialists in the areas of both Gastroenterology and Liver disease.

To find out how to submit a poster for this and future symposia to have the chance of winning one of three prizes for EUR 1500, 1000 and 500 along with attending the meetings don't forget to click below.

Click Here

Looking ahead: Dr Falk cordially invites you to the following Falk Forums

20th November: Dr Gordon Moran and The Nottingham Digestive Diseases Centre along with the NIHR Biomedical Research Unit are looking forward to welcoming you to the 47th Falk Forum entitled Inflammatory Bowel Disease and Associated Liver Disease.

Click Here

4th December in Exeter: Dr. Tariq Ahmad will be welcoming you to the 49th Falk Forum at the Royal Devon and Exeter NHS Foundation Trust. It will be focused on the prevention and management of adverse drug reactions in patients with inflammatory bowel disease.

Click Here
Dr Falk Resources

Dr Falk Resources

Extremely positive feedback from the Gastroenterology Team at the Royal Liverpool University Hospital regarding the newly launched Dr Falk Academy Workshops. Could your clinical team benefit from this free service?

A unique, innovative service, the Academy offers flexible or bespoke workshops, organised by Dr Falk representatives and delivered by expert trainers, completely tailored to the needs of individual healthcare groups in both primary and secondary care. Paul Collins, Consultant Gastroenterologist at the Royal Liverpool University Hospitals, and his team provide their viewpoint of the workshop.

Click Here to Read More
Dr Falk Media Update

Media Update

Are PBC Patients in the UK being significantly undiagnosed?

Over a quarter of all patients with Primary Biliary Cirrhosis are going undiagnosed by their GP for over three years or more with potentially life threatening consequences.

This is the startling finding of a survey carried out by the PBC Foundation, in conjunction with Dr Falk Pharma UK, earlier this year.

Click Here to Read More
Facebook Circle Share Twitter Circle Tweet Email Circle Forward
Footer Image

Copyright © 2015 Dr Falk, All rights reserved. Agreement to being contacted by Dr Falk Pharma

Our mailing address is:

Dr Falk
Unit K/Bourne End Business Pk/Cores End Rd
Bourne End, Buckinghamshire SL8 5AS
United Kingdom

Add us to your address book

Unsubscribe from this list   Update subscription preferences






This email was sent to <<Email Address>>
why did I get this?    Unsubscribe from this list      Update Profile
Dr Falk · Unit K/Bourne End Business Pk/Cores End Rd · Bourne End, Buckinghamshire SL8 5AS · United Kingdom

Email Marketing Powered by Mailchimp